Scarica l'app Stockscreener
1.16
16.00%
0.16
Dopo l'orario di chiusura:
1.17
0.01
+0.86%
Precedente Chiudi:
$1.00
Aprire:
$1.02
Volume 24 ore:
3.65M
Relative Volume:
3.84
Capitalizzazione di mercato:
$4.95M
Reddito:
-
Utile/perdita netta:
$-6.78M
Rapporto P/E:
-0.0272
EPS:
-42.6996
Flusso di cassa netto:
$-4.67M
1 W Prestazione:
+17.31%
1M Prestazione:
+30.85%
6M Prestazione:
-19.44%
1 anno Prestazione:
-29.27%
Intervallo 1D:
$1.02
$1.25
Intervallo di 1 settimana:
$0.9575
$1.25
Portata 52W:
$0.80
$2.18
Clearmind Medicine Inc Stock (CMND) Company Profile
Nome
Clearmind Medicine Inc
Settore
Industria
Telefono
-
Indirizzo
-
Confronta CMND con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CMND
Clearmind Medicine Inc
|
1.16 | 5.32M | 0 | -6.78M | -4.67M | -42.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Clearmind Medicine Inc Borsa (CMND) Ultime notizie
Is Clearmind Medicine Inc. a good long term investmentExplosive earnings growth - jammulinksnews.com
How Clearmind Medicine Inc. stock reacts to Fed policy changesFree Access to Community with 300% Return - beatles.ru
What drives Clearmind Medicine Inc. stock priceExceptional gains - Autocar Professional
What analysts say about Clearmind Medicine Inc. stockUnstoppable profit momentum - jammulinksnews.com
Clearmind Medicine Inc. Stock Analysis and ForecastPhenomenal trading returns - jammulinksnews.com
What makes Clearmind Medicine Inc. stock price move sharplySmart Money Trade Setups - beatles.ru
Clearmind Expands its Clinical Trial for Alcohol Use, New Site Activated and Additional Participant Enrolled - MarketScreener
How Clearmind Medicine Inc. stock performs during market volatilityFree High-Accuracy Stock Picks - Newser
Why Clearmind Medicine Inc. stock attracts strong analyst attentionTriple Return With Stability - Newser
Clearmind Expands Its Clinical Trial for Alcohol Use: New Site Activated and Additional Participant Enrolled - MarketScreener
Clearmind expands phase I/IIa trial for alcohol use disorder treatment By Investing.com - Investing.com South Africa
Clearmind expands phase I/IIa trial for alcohol use disorder treatment - Investing.com India
Clearmind Medicine Inc. Expands Phase I/IIa Clinical Trial for CMND-100 to Johns Hopkins University to Address Alcohol Use Disorder - Nasdaq
Clearmind Expands its Clinical Trial for Alcohol Use: New Site Activated and Additional Participant Enrolled - The Manila Times
Clearmind Medicine (NASDAQ:CMND) Stock Price Up 4.5% – Here’s Why - Defense World
Alcohol Use Disorder Market Report 2025-2035 Featuring Clearmind Medicine, Purdue Pharma, Psyence Biomedical, Eli Lilly and Co, Tempero Bio,, Nxera Pharma, Novo Nordisk, Adial, Alkermes, Lundbeck - Yahoo Finance
Clearmind Medicine Soars 32.89% on Clinical Trial Approval - AInvest
CMND’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
Clearmind Gains IRB Approval At TASMC For Alcohol Use Disorder Drug Trial - Nasdaq
Clearmind’s Stock Gains Momentum with New Trial Expansions - timothysykes.com
Clearmind Medicine’s Rise: What’s Steering the Surge? - timothysykes.com
Clearmind receives IRB approval for alcohol disorder treatment trial - Investing.com
Clearmind receives IRB approval for alcohol disorder treatment trial By Investing.com - Investing.com South Africa
Clearmind Medicine Inc. Receives IRB Approval for Phase 1/2a Clinical Trial of CMND-100 for Alcohol Use Disorder - Nasdaq
Clearmind Medicine Announces First Participant Ever Dosed with its CMND-100 Treatment in Groundbreaking Clinical Trial for Alcohol Use Disorder - The Manila Times
Clearmind doses first participant in alcohol disorder treatment trial - Investing.com
Clearmind doses first participant in alcohol disorder treatment trial By Investing.com - Investing.com Canada
Clearmind Medicine's Global AUD Trial Expansion: Seizing the $775M Market's Psychedelic Opportunity - AInvest
Clearmind adds Hadassah Medical Center to alcohol disorder drug trial By Investing.com - Investing.com South Africa
Clearmind Adds New Site to Trial for Experimental Alcohol Use Disorder Drug - MarketScreener
Clearmind enrolls first patient in CMND-100 alcohol disorder trial - Investing.com India
Clearmind Medicine Enrolls First Patient in its Clinical Trial for Alcoholism Treatment - Yahoo Finance
Clearmind Medicine Inc. Engages Consulting Firm to Advance Psychedelic-Based Treatments and Regulatory Advocacy - Nasdaq
Clearmind adds Tel Aviv medical center to alcohol disorder drug trial - Investing.com India
Clearmind Medicine Inc. Expands Phase I/IIa Clinical Trial for CMND-100 with Tel Aviv Sourasky Medical Center Collaboration - Nasdaq
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
Clearmind Medicine Inc. (NASDAQ:CMND) Short Interest Update - Defense World
Clearmind Medicine Retains Crescendo Communications LLC. for Investor Relations and Announces Granting of Stock and Warrants - Psychedelic Alpha
Clearmind Medicine Inc. (NASDAQ:CMND) Shares Acquired by Citadel Advisors LLC - Defense World
# Clearmind Medicine hires lobbying firm to advance psychedelic therapy By Investing.com - Investing.com South Africa
# Clearmind Medicine hires lobbying firm to advance psychedelic therapy - Investing.com Australia
Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic Therapeutics - The Manila Times
Clearmind Medicine Partners with Leading Government Affairs Firm to Advance Psychedelic Therapeutics - Nasdaq
Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic ... - Bluefield Daily Telegraph
Clearmind Medicine Inc Azioni (CMND) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.87%
0.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):